First Line Regimen Durability and Adverse Events

Understanding the implications of the side effect profile of individual antiretroviral drugs as well as the durability of drug regimens has considerable significance in settings where resources and drug options for HIV remain limited. HE2RO has explored these questions through longitudinal patient datasets with a particular interest in the effects of tenofovir upon introduction into the national programme. These analyses are ongoing as guidelines continue to evolve and current projects include a pharmacovigilence study in collaboration with researchers at the University of Cape Town.


The following publications emanate from this project:

Funded by


HE2RO staff involved

Dr. Lawrence Long   Dr. Matthew Fox   Dr. Denise Evans   Dr Mhairi Maskew   Dr. Kate Shearer  

Stay up to date

Receive newsletters and keep up to date with developments at HE2RO.